AUS
NZ
UK
CA
USA
IND
It's been a tough day for the S&P/ASX 200 Index, which has dropped 1.30%, pulling it below 7,700 points. However, one healthcare stock is defying the trend and making significant gains on Wednesday. Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) is seeing a remarkable rise, standing out in a generally bearish market.
Stellar Performance Amid Market Slump
On Tuesday, Fisher & Paykel shares closed at AU$25.45. This morning, the shares opened at AU$26.55 and have climbed to AU$26.51, marking a 4.17% increase. Notably, the shares reached a new 52-week high of AU$27.50 just before midday.
This rise is not an isolated event. Fisher & Paykel's stock is up 20.5% for the year and 16.7% over the past 12 months. So, what's driving this impressive performance?
Strong Earnings Propel Shares Higher
The catalyst for today's gains appears to be the company's earnings report, released before the market opened. Fisher & Paykel reported revenues of NZ$1.74 billion for the full year ending 31 March 2024, a 10% increase from the previous year. This boost in revenue helped the company achieve an underlying net profit after tax (NPAT) of NZ$264.4 million, a 6% rise from the prior year.
Fisher & Paykel's gross margins also improved, climbing 2.16% to 61.1%. These strong financials enabled the company to announce a dividend of 23.5 cents per share, payable on 10 July. This brings the total full-year dividend to 41.5 cents per share, up 2% from FY2023.
CEO's Optimistic Outlook
CEO Lewis Gradon expressed satisfaction with the results, emphasizing the company's return to growth. "After several years of changing demand patterns, we are pleased to have returned to a trajectory of growth. All the right foundations are in place for future success – we have an impressive portfolio of products, strong relationships with our customers, and the right infrastructure to meet our future needs," Gradon stated.
He further highlighted the company's 50-year track record and its commitment to introducing new solutions that benefit patients and drive sustainable, profitable growth for shareholders.
Future Prospects
Looking ahead, Fisher & Paykel has provided optimistic guidance for the 2025 financial year. The company anticipates revenues between NZ$1.9 billion and NZ$2 billion, with a net profit after tax ranging from NZ$310 million to NZ$360 million.
